Key Takeaways
- PayPal (PYPL) stock declined after issuing subdued 2026 profit guidance, yet turnaround opportunities persist through improved checkout experiences and Venmo expansion
- CVS Health (CVS) delivered $402.1 billion in 2025 annual revenue and projected revenue exceeding $400 billion for 2026
- Nike (NKE) stock generated $11.3 billion in third-quarter 2026 revenue with a 5% wholesale increase and positive North American momentum
- HP (HPQ) stock reported first-quarter 2026 revenue of $14.4 billion, reflecting 6.9% annual growth, while maintaining free cash flow projections between $2.8–$3.0 billion
- Estée Lauder (EL) stock fell despite exceeding profit estimates, as its fiscal 2026 outlook failed to satisfy investor expectations
Investors scanning for undervalued opportunities in 2026 are keeping close tabs on PayPal (PYPL) stock, CVS Health (CVS) stock, Nike (NKE) stock, HP (HPQ) stock, and Estée Lauder (EL) stock.
These companies aren’t just trading at bargain prices. They represent a specific investment thesis: depressed market sentiment combined with tangible operational improvements that could trigger valuation re-ratings.
Companies Executing Turnarounds
PayPal (PYPL) Stock
PayPal stands out as a textbook case of diminished expectations potentially setting up for reversal. According to Reuters reporting in February, the digital payments giant projected adjusted profit for 2026 would remain flat or decline slightly, falling short of analyst consensus.
Shares tumbled following executive transitions that created uncertainty about strategic direction. However, if the new leadership team successfully accelerates branded checkout adoption and unlocks additional Venmo revenue streams, PayPal (PYPL) stock could begin trading like a fintech platform in recovery mode rather than decline.
CVS Health (CVS) Stock
CVS Health remains attractively priced considering its massive operational scale. The healthcare giant posted 2025 full-year revenue totaling $402.1 billion. For 2026, executives provided adjusted earnings per share guidance ranging from $7.00 to $7.20, built on a revenue base of at least $400 billion.
CVS Health (CVS) stock doesn’t require a dramatic transformation to appreciate. Moderate margin expansion across its insurance and pharmacy operations could be sufficient for investors to view it as a stable cash-generating enterprise.
Nike (NKE) Stock
Nike continues to be viewed by investors as a complicated turnaround story with numerous variables. The athletic apparel leader disclosed fiscal third-quarter 2026 results on March 31, posting $11.3 billion in revenue with wholesale channels advancing 5%. The North American market also delivered growth.
Gross margins compressed, and certain segments remain challenged. Nevertheless, selective areas are demonstrating positive momentum, which is typically where undervalued investment opportunities emerge.
Free Cash Flow and Stabilization Opportunities
HP (HPQ) Stock
HP disclosed fiscal first-quarter 2026 revenue of $14.4 billion, representing a 6.9% year-over-year increase. Non-GAAP diluted earnings per share climbed 9.5%, while free cash flow reached $175 million. The technology company reaffirmed its full-year free cash flow target of $2.8 billion to $3.0 billion.
The investment thesis for HP (HPQ) stock hinges on sustained PC market stabilization and accelerating demand for AI-enabled computers. HP doesn’t need explosive revenue expansion to deliver shareholder returns—simply maintaining earnings stability could drive multiple expansion.
Estée Lauder (EL) Stock
Estée Lauder represents the most speculative opportunity among these five names. Reuters reported in February that shares declined following disappointing fiscal 2026 guidance, despite the prestige beauty company surpassing profit forecasts.
Executives outlined a turnaround strategy centered on new product introductions, enhanced marketing initiatives, and reinforced premium brand positioning. The market remains concerned about softening U.S. consumer demand, tariff headwinds, and execution challenges.
Based on current guidance, Estée Lauder (EL) stock has yet to demonstrate sustainable sales momentum or margin improvement.
Bottom Line
These five stocks share a unifying characteristic. Market sentiment remains subdued, yet each company possesses genuine catalysts that could fundamentally alter investor perception throughout 2026.
